CCM
CADL icon

CAAS Capital Management’s Candel Therapeutics CADL Stock Holding History

CAAS Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$542K – 881
2021
Q3 		$542K Buy
+50,000
New +$415K 0.01% 599

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's CADL Position: Q4 2021 in Review

CAAS Capital Management sold out of Candel Therapeutics (CADL) in Q4 2021, closing a stake of 50,000 shares — an estimated $542K sold.

CAAS Capital Management first reported a position in CADL in Q3 2021 and held it in 1 quarter. The position peaked at $542K in Q3 2021. 20 funds tracked by Wall St. Rank hold CADL as of Q4 2021.

  • CAAS Capital Management reported no remaining Candel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 50,000 Candel Therapeutics shares in Q4 2021, an estimated $542K.
  • CAAS Capital Management first reported a position in Candel Therapeutics in Q3 2021 and held it in 1 quarter.
  • CAAS Capital Management's Candel Therapeutics position peaked at $542K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held Candel Therapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.